Could a statin help save babies from early delivery?

NCT ID NCT07098975

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a daily dose of pravastatin, a common heart medication, can safely prolong pregnancy in women diagnosed with severe early-onset preeclampsia or fetal growth restriction. The trial will include 154 pregnant women between 24 and 30 weeks of gestation, randomly assigned to receive either pravastatin or a placebo. The goal is to see if the drug can delay delivery and improve outcomes for both mother and baby.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Pravastatin 40 mg
What this could lead to
If it works, this could offer a way to safely prolong pregnancy in women with placental insufficiency, reducing complications from early delivery.
What could go wrong
This is a Phase 2 trial with only 154 participants, so results are preliminary. Statins are generally safe but not yet proven for this use in pregnancy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INTRAUTERINE GROWTH RESTRICTION (IUGR) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Hospital Clínic de Barcelona

    NOT_YET_RECRUITING

    Barcelona, Spain

  • Hospital de la Santa Creu i de Sant Pau

    RECRUITING

    Barcelona, 08025, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.